Cargando…

Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds

Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Qiu, Weimin, Sun, Tianyu, Wang, Lei, Du, Chenxi, Hu, Yanyu, Liu, Wenyuan, Feng, Feng, Chen, Yao, Sun, Haopeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279645/
https://www.ncbi.nlm.nih.gov/pubmed/35847506
http://dx.doi.org/10.1016/j.apsb.2021.12.019
_version_ 1784746444993855488
author Liu, Hui
Qiu, Weimin
Sun, Tianyu
Wang, Lei
Du, Chenxi
Hu, Yanyu
Liu, Wenyuan
Feng, Feng
Chen, Yao
Sun, Haopeng
author_facet Liu, Hui
Qiu, Weimin
Sun, Tianyu
Wang, Lei
Du, Chenxi
Hu, Yanyu
Liu, Wenyuan
Feng, Feng
Chen, Yao
Sun, Haopeng
author_sort Liu, Hui
collection PubMed
description Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma.
format Online
Article
Text
id pubmed-9279645
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92796452022-07-15 Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds Liu, Hui Qiu, Weimin Sun, Tianyu Wang, Lei Du, Chenxi Hu, Yanyu Liu, Wenyuan Feng, Feng Chen, Yao Sun, Haopeng Acta Pharm Sin B Review Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma. Elsevier 2022-04 2021-12-31 /pmc/articles/PMC9279645/ /pubmed/35847506 http://dx.doi.org/10.1016/j.apsb.2021.12.019 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Liu, Hui
Qiu, Weimin
Sun, Tianyu
Wang, Lei
Du, Chenxi
Hu, Yanyu
Liu, Wenyuan
Feng, Feng
Chen, Yao
Sun, Haopeng
Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title_full Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title_fullStr Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title_full_unstemmed Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title_short Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
title_sort therapeutic strategies of glioblastoma (gbm): the current advances in the molecular targets and bioactive small molecule compounds
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279645/
https://www.ncbi.nlm.nih.gov/pubmed/35847506
http://dx.doi.org/10.1016/j.apsb.2021.12.019
work_keys_str_mv AT liuhui therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT qiuweimin therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT suntianyu therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT wanglei therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT duchenxi therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT huyanyu therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT liuwenyuan therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT fengfeng therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT chenyao therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds
AT sunhaopeng therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds